激素替代治疗冻胚移植中「标准阴道孕酮方案」的预期效果——一项PRISMA综述与荟萃分析
该PRISMA综述与荟萃分析纳入24项研究,对五种阴道微粒化孕酮产品进行随机效应比例荟萃分析,共11,014例患者。Cyclogest(800 mg)与Crinone(180 mg或270 mg)、Utrogestan/Progestan(600 mg或800 mg)及Lutinus(300 mg)比较,血清孕酮浓度差异有统计学意义;但等效日剂量产品间无显著差异。作者认为不同阴道孕酮产品及给药方案的血清孕酮浓度存在显著差异,行HRT-FET时须加以考虑。
要点
- Cyclogest 800 mg与Crinone 180 mg或270 mg的血清孕酮浓度差异有统计学意义(P=0.01)。
- Cyclogest 800 mg与Utrogestan/Progestan 600 mg或800 mg差异有统计学意义(P=0.03)。
- 等效日剂量产品间血清孕酮浓度无显著差异。
核心结论
- 不同阴道孕酮产品及给药方案的血清孕酮浓度存在显著差异,行HRT-FET时必须加以考虑。
研究设计与样本
- PRISMA综述与荟萃分析,共纳入24项研究,对五种阴道微粒化孕酮产品行随机效应比例荟萃分析,合计11,014例患者。
- 纳入标准:使用阴道孕酮产品且报告血清孕酮浓度与方案;无额外孕酮或孕激素治疗;前瞻性与回顾性研究设计均纳入。
- 排除非英文发表的摘要与全文。
主要发现
- Cyclogest(800 mg)与Crinone(180 mg或270 mg)比较,血清孕酮浓度差异有统计学意义(P=0.01)。
- Cyclogest(800 mg)与Utrogestan/Progestan(600 mg或800 mg)比较,差异有统计学意义(P=0.03)。
- Cyclogest(800 mg)与Lutinus(300 mg)比较,差异有统计学意义(P=0.01)。
- 等效日剂量的产品之间未发现显著差异。
关键数值与推荐
- 黄体中期血清孕酮浓度低于9-11 ng/ml对HRT-FET生殖结局有负面影响,因无黄体存在,该浓度反映所给孕酮产品的吸收。
临床怎么用
- 原文结论指出,不同阴道孕酮产品及给药方案的血清孕酮浓度存在显著差异,行HRT-FET时必须加以考虑;原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A mid-luteal serum progesterone concentration below 9-11 ng/ml has been shown to have a negative impact on reproductive outcomes in hormone replacement therapy frozen embryo transfer (HRT-FET), and as no corpus luteum is present, this concentration reflects the absorption of the progesterone products administered. However, the composition and dosing regimens of vaginal products vary. In total, 24 studies were included in this review, selected according to the following criteria: the use of vaginal progesterone products, with serum progesterone concentration and regimens reported; the absence of additional progesterone or progestin treatments; and the use of both prospective and retrospective study designs. Abstracts and full texts published in languages other than English were excluded. A random-effects proportional meta-analysis of five different vaginal micronized progesterone products was performed, including a total of 11,014 patients. Significant differences were found when comparing Cyclogest (800 mg) with Crinone (180 mg or 270 mg) (P = 0.01); Cyclogest (800 mg) with Utrogestan/Progestan (600 mg or 800 mg) (P = 0.03); and Cyclogest (800 mg) with Lutinus (300 mg) (P = 0.01). However, no significant differences were identified between products with an equivalent daily dose. In conclusion, significant differences in serum progesterone concentration exist between different vaginal progesterone products and dosing regimens, which must be taken into account when performing HRT-FET.
引用
- Alsbjerg B, Humaidan P. What to expect from a 'standard vaginal progesterone regimen' in hormone replacement therapy frozen embryo transfer (HRT-FET) - a PRISMA review and meta-analysis. Reprod Biomed Online. 2024. PMID: 40132465. doi:10.1016/j.rbmo.2024.104736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。